Navigation Links
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Date:11/7/2013

"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, the potential for health authority approvals of naloxegol, the projected timeframe in which the NKTR-181 Phase 3 clinical study would be commenced, the timing of regulatory filings with health authorities for BAX 855, and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials, regulatory approval decisions, and the commercial launch of our drug candidates may be
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 31, 2011 Leading events organiser UBM Live ... details of a new Logistics and Supply Chain Zone ... to pharmaceutical contract services and outsourcing. ICSE will take ... Germany and is part of the world,s leading platform ...
... (NASDAQ: UPI ), announced today that the ... (NICE) issued guidance on percutaneous tibial nerve stimulation (PTNS) ... NICE issued similar guidance on PTNS treatment for overactive ... in the UK and Europe to use our Urgent® ...
Cached Medicine Technology:Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 2Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 3United Kingdom's National Institute for Health and Clinical Excellence Issues Guidance on Percutaneous Tibial Nerve Stimulation for Faecal Incontinence 2
(Date:7/10/2014)... 2014 Up to 70% of Parkinson,s disease ... their quality of life. Some patients have disturbed ... staying asleep, while other patients may be subject ... the extreme, PD patients may exhibit REM-sleep behavior ... dream re-enactment, even before motor symptoms appear. A ...
(Date:7/10/2014)... of Huddersfield could help to improve the quality of ... such as butter, mayonnaise, yoghurt and fruit drinks ... for her work. , Katerina gained her MSc degree ... now she has embarked on research for a PhD. ... is investigating the potential of carbohydrates extracted from the ...
(Date:7/10/2014)... 2014) A research review identifying the clinical indicators ... step in the process of developing evidence-based guidelines for ... report published by Neurosurgery , official ... . The journal is published by Lippincott Williams ... Kluwer Health . , Based on analysis of ...
(Date:7/10/2014)... decades, health-conscious people around the globe have taken antioxidant ... was one of the paths to good health and ... of antioxidant supplements have repeatedly dashed the hopes of ... risk. Virtually all such trials have failed to ... in several trials antioxidant supplementation has been linked with ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2
... five-year international clinical study shows that acyclovir, a commonly prescribed ... not affect HIV transmission by people with both viruses. ... Transmission Study, was released by the New England Journal ... will follow in the print edition Feb. 4. ...
... ... Second Wave of H1N1 Flu: No Waiting in Long Lines , ... San Diego, Calif. (Vocus) January 25, 2009 -- U.S. ... nation, announced today that they are offering H1N1 vaccine shots for $15 per shot for ...
... for surgery than county hospitals, research shows , MONDAY, ... received by prostate cancer patients is influenced by the ... a new U.S. study has found. , Surgery was ... while patients in private facilities were more likely to ...
... , ROCHESTER, Minn. , Jan. ... the brain is the aim of a new Mayo Clinic project ... The new method uses analytics technology developed by the Mayo and ... 95 percent accuracy rate in detecting aneurysms, compared with 70 percent ...
... , NEW YORK , ... of the 25 largest PR firms ( http://www.5wpr.net/ ) in the U.S., today ... its versatile roster of fashion and lifestyle clients. Launched in 2002, the luxury ... lifestyle products using proprietary natural frequency technology. , " Philip Stein is ...
... CHESAPEAKE, Va. , Jan. 25 U.S.-based, Maison ... Haiti -based Maison Fortune Orphanage. The strategic expansion plans ... after the recent devastating earthquakes. The Orphanage, located near the ... in a sea of unimaginable turmoil. , This planned expansion ...
Cached Medicine News:Health News:Control of herpes symptoms does not reduce HIV transmission, international study found 2Health News:U.S. HealthWorks in San Diego Region Offering $15 H1N1 Vaccinations for both Walk-Ins and On-Site 2Health News:Prostate Cancer Care Varies By Hospital Type 2Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 2Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 3Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 4Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 2Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 3Health News:Haitian Orphanage Takes Quick Action to Fill Void after Devastating Earthquakes 2Health News:Haitian Orphanage Takes Quick Action to Fill Void after Devastating Earthquakes 3
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
... a comprehensive, authoritative drug reference to ... overdose management, Canadian drug names, OTC ... drug references and tools is included ... (ED, PRIMARY CARE PLUS, CRC, RN, ...
... patients and health consumers from the trusted ... in MedMaster includes why the medication is ... side effects and warning signs of adverse ... information on what to do if a ...
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Medicine Products: